During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

41.7% with nivolumab/ipilimumab, and 23% with nivolumab). Similar differences existed for clinical to pathologic downstaging after neoadjuvant therapy (46.7%, 41.7%, and 23%). Patients who had a ...

Patients with MSI-H mCRC had a higher probability of survival with first-line ICI therapy than with chemotherapy, but second-line or later ICIs did not confer the same benefit.

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often persisting for years.

The study randomly assigned 42 patients (one would later withdraw consent) to three immunotherapy treatment arms: nivolumab ...

Reference #21 should have been “Geynisman DM, Faccone J, Zhang Y, et al. Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell ...

Gut microbiota composition may influence the efficacy and safety of chemo-immunotherapy in advanced non-small cell lung cancer. Read now.

Skin cancer advanced clinical practitioners ensure continuity of care for patients with malignant melanoma and other advanced ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two ...